Alpine Associates Management Inc. Takes Position in Sucampo Pharmaceuticals, Inc. (SCMP)

Alpine Associates Management Inc. acquired a new stake in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,495,600 shares of the biopharmaceutical company’s stock, valued at approximately $26,845,000. Sucampo Pharmaceuticals makes up 1.0% of Alpine Associates Management Inc.’s portfolio, making the stock its 24th biggest position. Alpine Associates Management Inc. owned about 3.17% of Sucampo Pharmaceuticals at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the company. The Manufacturers Life Insurance Company lifted its position in shares of Sucampo Pharmaceuticals by 4.1% in the second quarter. The Manufacturers Life Insurance Company now owns 19,983 shares of the biopharmaceutical company’s stock valued at $209,000 after acquiring an additional 790 shares in the last quarter. Thrivent Financial For Lutherans lifted its position in shares of Sucampo Pharmaceuticals by 11.3% in the second quarter. Thrivent Financial For Lutherans now owns 15,270 shares of the biopharmaceutical company’s stock valued at $160,000 after acquiring an additional 1,550 shares in the last quarter. Ameriprise Financial Inc. lifted its position in shares of Sucampo Pharmaceuticals by 1.3% in the second quarter. Ameriprise Financial Inc. now owns 131,790 shares of the biopharmaceutical company’s stock valued at $1,384,000 after acquiring an additional 1,690 shares in the last quarter. Teachers Advisors LLC lifted its position in shares of Sucampo Pharmaceuticals by 2.9% in the second quarter. Teachers Advisors LLC now owns 68,499 shares of the biopharmaceutical company’s stock valued at $719,000 after acquiring an additional 1,953 shares in the last quarter. Finally, Voya Investment Management LLC lifted its position in shares of Sucampo Pharmaceuticals by 22.7% in the second quarter. Voya Investment Management LLC now owns 13,411 shares of the biopharmaceutical company’s stock valued at $141,000 after acquiring an additional 2,477 shares in the last quarter. Institutional investors and hedge funds own 67.09% of the company’s stock.

Several brokerages have recently issued reports on SCMP. BidaskClub downgraded Sucampo Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Zacks Investment Research downgraded Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, February 9th. ValuEngine upgraded Sucampo Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 2nd. Nomura restated a “neutral” rating and issued a $18.00 price objective on shares of Sucampo Pharmaceuticals in a research report on Friday, January 26th. Finally, UBS Group downgraded Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $18.00 price objective on the stock. in a research report on Friday, January 5th. Eight research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $20.25.

Sucampo Pharmaceuticals, Inc. (NASDAQ SCMP) opened at $18.00 on Wednesday. Sucampo Pharmaceuticals, Inc. has a 12-month low of $9.30 and a 12-month high of $18.75. The firm has a market capitalization of $849.02, a PE ratio of -5.47, a P/E/G ratio of 5.06 and a beta of 1.38. The company has a debt-to-equity ratio of 7.37, a quick ratio of 4.46 and a current ratio of 5.11.

In other news, insider Peter A. Kiener sold 50,000 shares of the firm’s stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $16.50, for a total value of $825,000.00. Following the transaction, the insider now directly owns 52,023 shares in the company, valued at approximately $858,379.50. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 4.13% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/14/alpine-associates-management-inc-takes-position-in-sucampo-pharmaceuticals-inc-scmp.html.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Want to see what other hedge funds are holding SCMP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP).

Institutional Ownership by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply